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Abstract
Background
Direct oral anticoagulants (DOACs) have emerged as promising alternatives to vitamin K
antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or venous throm-
boembolism (VTE). Few meta-analyses have included all DOACs that have received FDA
approval for these cardiovascular indications, and their overall comparisons against VKAs
have shortcomings in data and methods. We provide an updated overall assessment of the
efficacy and safety of those DOACs at dosages currently approved for NVAF or VTE, in
comparison with VKAs.
Methods
We used data from Phase 3 randomized trials that compared an FDA-approved DOAC with
VKA for primary prevention of stroke in patients with NVAF or for treatment of acute VTE.
Results
Among trial participants with NVAF, DOAC recipients had a lower risk of stroke or systemic
embolism [Pooled Odds Ratio (OR) 0.76, 95% Confidence Interval (CI) (0.68–0.84)], any
stroke (0.80, 0.73–0.88), systemic embolism (0.56, 0.34–0.93), and total mortality (0.89,
0.84–0.95). Safety outcomes also showed a lower risk of fatal, major, and intracranial bleed-
ing but higher risk for gastrointestinal bleeding (GIB). Patients with acute VTE randomized
to DOACs had comparable risk of recurrent VTE and death (OR 0.88, 95% CI 0.75–1.03),
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recurrent DVT (0.83, 0.66–1.05), recurrent non-fatal PE (0.97, 0.75–1.25), and total mortal-
ity (0.94, 0.79–1.12). Safety outcomes for DOACs showed a lower risk of major, fatal, and
intracranial bleeding, but similar risk of GIB.
Conclusions
Patients receiving DOACs for NVAF had predominantly superior efficacy and safety.
Patients who were treated with DOACs for acute VTE had non-inferior efficacy, but an over-
all superior safety profile.
Introduction
Since the approval of dabigatran by regulatory agencies in Europe and Canada in 2008[1, 2],
and in the United States in 2010[3], the use of direct oral anticoagulants (DOACs) has
increased dramatically[4, 5]. Four DOACs, the direct thrombin inhibitor dabigatran and the
Factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, are currently approved for use in
Europe. The U.S. guidelines recommend these agents as alternatives to vitamin K antagonists
(VKAs) for prevention of thromboembolism in patients with non-valvular atrial fibrillation
(NVAF) and for treatment of acute venous thromboembolism (VTE)[6–10].
The increase in prescriptions for DOACs in patients with these cardiovascular indications
reflects several advantages for DOACs over VKAs, including fixed-dose administration, fewer
drug-drug interactions, and limited dietary restrictions. Although clinical trials have demon-
strated at least equivalent therapeutic efficacy of these newer agents[11–19], concerns about
the safety profile and net clinical benefit of DOACs have remained, perhaps because of anec-
dotal reports of adverse outcomes and experience with some early DOACs, which were with-
drawn from the market because of serious adverse events[20–22]. The uncertainty arising
from conflicting results from clinical trials, post-market surveillance and observational studies,
and systematic reviews[23–28], issues of long-term safety and higher cost, and the absence of
approved reversal agents for Factor Xa antagonists[29] are of particular concern to patients,
pharmacists, and clinicians, limiting the routine use of DOACs even among those with
approved indications[30].
Most systematic reviews and meta-analyses that have examined the efficacy and safety of
DOACs were conducted before the FDA approved edoxaban for use in patients with NVAF
and VTE in 2015[31]. Many also included studies that used DOACs for multiple cardiac and
non-cardiac conditions and at various dosages, many of which were eventually not approved
for clinical use by the FDA. Although including such an expanded list of indications might be
valuable for a researcher, the practicing cardiologist is often more interested in the expected
outcomes associated with the use of a specific medication, when used for approved cardiovas-
cular indications alone and at FDA-approved dosages, as relevant to their current clinical prac-
tice. Finally, several methodological shortcomings in prior meta-analyses (described in S10
File) raise doubts about applying their conclusions to the contemporary use of DOACs in
patients with specific cardiovascular indications.
To address ongoing concerns about the efficacy, safety, and net clinical benefit of DOACs
as a therapeutic class when used for on-label cardiovascular indications, we performed a sys-
tematic review and meta-analysis of important efficacy and safety outcomes. The data came
from all high-quality Phase 3 randomized clinical trials of the 4 FDA-approved DOACs at
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currently approved dosages for prevention of thromboembolic stroke in patients with NVAF
and for treatment of acute VTE.
Methods
Search strategy
We performed a contemporary systematic review of the published literature in accordance
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (S1 File). We searched PubMed (including MEDLINE) and Scopus (including
Embase) databases and Cochrane libraries for randomized trials published from inception of
the databases through July 2016. We also searched on Google Scholar and reviewed citations
of published review articles to find additional clinical trials. The search terms and protocol for
this systematic review and meta-analysis are documented in S2 File.
Study selection
To be included in this meta-analysis, a Phase 3 clinical trial must have been reported in English
and have compared dabigatran, apixaban, rivaroxaban, or edoxaban at standard dosages (as
described in S2 File) versus warfarin (dose-adjusted to achieve an international normalized
ratio between 2.0 and 3.0) for prevention of thromboembolism in patients with NVAF or for
treatment of acute VTE. We excluded studies of DOACs for indications other than these two
conditions (e.g., DVT prophylaxis in patients undergoing hip and knee surgery) or only at dos-
ages other than those approved by the FDA. In stages, we reviewed each article’s title, abstract,
and full text to eliminate articles that did not meet our pre-specified inclusion/exclusion
criteria.
Data collection and abstraction
For randomized trials meeting our inclusion criteria, two researchers (HT and RP) indepen-
dently extracted pertinent information onto a standard data collection form (S5 File). Informa-
tion abstracted included: lead author’s name, year of publication, clinical trial name, treatment
indication, DOAC studied, dosages, comparator, participants’ age and sex, follow-up duration,
and all efficacy and safety outcomes. The two reviewers resolved discrepancies through discus-
sions between themselves and senior study investigators.
Study outcomes
The study outcomes considered were the occurrence of stroke and systemic embolism (pri-
mary efficacy outcome for NVAF), any stroke, fatal and non-fatal PE, myocardial infarction,
death from vascular causes, recurrent DVT or PE, recurrent VTE and related death (primary
efficacy outcome for VTE), all-cause mortality, bleeding (major bleeding, fatal bleeding, intra-
cranial bleeding, gastrointestinal (GI) bleeding, blood loss >2g/dl, blood transfusion of more
than 2 units, intramuscular bleeding, non-intracranial/non-GI bleeding, and any overt bleed-
ing), and other adverse drug events (ADEs) such as purpura, dizziness, diarrhea, edema,
fatigue, epistaxis, headache, and serum liver transaminase levels greater than three times the
upper limit of normal. An additional secondary outcome in some VTE trials was net clinical
benefit, defined as the composite endpoint of recurrent VTE or a major bleeding episode.
Because the sample sizes for several outcomes were relatively small, our analysis used 7 efficacy
and 4 safety outcomes for trials in patients with NVAF and 7 efficacy and 8 safety outcomes
for trials in patients with VTE.
Efficacy and safety of direct oral anticoagulants
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Statistical analysis
Because direct thrombin inhibitors and factor Xa inhibitors all act on the coagulation cascade,
we considered the 4 DOACs as a single drug class and did not analyze differences among
them. We carried out separate analyses of studies in patients with NVAF and VTE for out-
comes that were reported by at least 3 trials. Since the trials were conducted under varying
circumstances, our meta-analyses used a random-effects model. We do not report the hetero-
geneity measure I2 because it has no useful interpretation (as explained in S7 File). The quanti-
tative measure of effect was the odds ratio (the ratio of the odds of an event in the DOAC arm
to the odds of an event in the comparator arm, further explained in S6 File). The number of
events and the number of subjects in each trial arm served as the data for a mixed-effects logis-
tic regression model, in which a random effect accounted for variation among the various
studies’ true log-odds-ratios. We used the lme4 package in R to conduct our analyses[32] (We
report details of the models in S9 File).
This study was not subject to IRB approval since it was a summary analysis of existing pub-
lished data.
Results
Searches of PubMed, Scopus, and the Cochrane libraries yielded a total of 406, 1,111, and
1,081 articles, respectively (Fig 1). After excluding 590 duplicate articles and 1,477 by title
review, we reviewed the abstracts of 531 articles for their possible relevance. Of the 58 articles
retained for full-text review, 8 had a non-clinical trial design, 5 were a secondary analysis of a
clinical trial, 28 studied patients with a non-approved or non-cardiac indication, 5 used non-
warfarin agents as control, and 3 articles did not have information on the study’s sample size
(S3 File). These exclusions left a total of 4 trials on stroke prevention in patients with NVAF
[11–14] and 5 trials in patients with VTE[15–19] for data extraction.
Study characteristics
The 9 randomized trials involved a total of 80,311 participants (58,271 in the NVAF trials and
22,040 in the VTE trials). The baseline characteristics of patients included in these trials are
summarized in Table 1. In the trials of patients with NVAF, the average age of study partici-
pants was 71.6 years (unweighted average over trials), and 37.4% were women. Study sample
sizes ranged from 12,037 to 18,201 patients, and the median duration of follow-up ranged
from 1.8 to 2.8 years. In the trials of patients with VTE, the average age of study participants
was 56.2 years, 41.6% were women, and study sample sizes ranged from 2,539 to 8,240 patients.
None of the trials of patients with VTE reported median duration of follow-up; follow-up was
longer than 1 year in one trial and longer than 6 months in the other four trials.
Publication bias and quality of included studies
To assess potential sources of bias, we used the Cochrane Collaboration’s risk-of-bias tool[33].
We determined that the overall risk of bias in each study was low (S4 File). The risk of selective
outcome reporting was determined to be minimal because included trials were Phase 3 ran-
domized trials and included outcomes adjudicated in a blinded fashion.
Reporting of trial events
Reporting on trial-related efficacy and safety outcomes varied widely among the studies
included. All 9 trials provided data on all-cause mortality and the main outcomes for their
respective indication, including stroke or systemic embolism, any stroke, hemorrhagic stroke,
Efficacy and safety of direct oral anticoagulants
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myocardial infarction, major bleeding, and intracranial bleeding in the NVAF trials and recur-
rent VTE and related death, recurrent DVT, major bleeding, and fatal bleeding in the VTE
trials. Fewer studies reported other efficacy and safety outcomes, especially ADEs such as ele-
vated serum transaminase levels, myocardial infarction, and miscellaneous symptoms such as
arthralgia, peripheral edema, or dyspepsia. S5 File lists the data extracted from the 9 included
studies.
Efficacy and safety outcomes in trials of DOACs for prevention of
thromboembolism in patients with non-valvular atrial fibrillation
In trials enrolling participants with NVAF, the odds of developing a stroke or systemic embo-
lism (the primary outcome in most studies of primary prevention in patients with NVAF) was
nearly one-quarter lower for patients treated with a DOAC than for those treated with warfarin
(pooled odds ratio (OR) 0.76). Patients treated with a DOAC had significantly lower odds of
developing any type of stroke (OR 0.80); the greatest benefit came from substantially lower
risk of hemorrhagic stroke (OR 0.49). Similarly, the risks of dying from any cause (OR 0.89)
and specifically from vascular causes (OR 0.86) were lower for patients treated with a DOAC
than for those treated with warfarin (Fig 2). Participants randomized to receive a DOAC also
had 15% lower odds of experiencing a major bleeding episode, 45% lower odds of experiencing
a fatal bleeding event, and 52% lower odds of experiencing an intracranial bleeding event than
participants randomized to receive warfarin therapy. However, participants with NVAF ran-
domized to receive a DOAC had one-quarter higher risk for GI bleeding than participants
who were treated with warfarin therapy (Fig 3).
Efficacy and safety outcomes in trials of DOACs for treatment in patients
with acute venous thromboembolism
In the five Phase 3 studies of DOACs for acute treatment of patients with a DVT, with or with-
out pulmonary embolism (PE), participants randomized to receive a DOAC did not differ
Fig 1. Study flow diagram.
https://doi.org/10.1371/journal.pone.0197583.g001
Table 1. Baseline characteristics and corresponding primary efficacy outcomes of the Phase 3 trials included.
NVAF Studies
Study Publication
Year
DOAC and dosing regimen Primary Events
/Total N
Comparator Primary Events
/Total N
Age
Years
Women
%
RE-LY 2009 Dabigatran 150mg twice daily 182/6015 Warfarin 199/6022 71.6 36.8
ARISTOTLE 2011 Apixaban 5mg twice daily 212/9120 Warfarin 265/9081 70.0 35.2
ROCKET AF 2011 Rivaroxaban 20mg daily 188/6958 Warfarin 241/7004 73.0 39.7
ENGAGE AF-
TIMI 48
2013 Edoxaban 60mg daily 296/7035 Warfarin 337/7036 72.0 37.7
VTE Studies
RE-COVER 2009 Dabigatran 150mg twice daily 30/1274 Warfarin 27/1265 55.5 41.6
EINSTEIN-DVT 2010 Rivaroxaban 15mg twice daily for 3
weeks, followed by 20mg daily
36/1731 Enoxaparin followed by
VKA
51/1718 56.1 43.2
AMPLIFY 2013 Apixaban 10mg twice daily for 7 days,
followed by 5mg twice daily
59/2609 Subcu. enoxaparin
followed by warfarin
71/2635 57.0 41.3
Hokusai-VTE 2013 Edoxaban 60mg daily 130/4118 Warfarin 146/4122 55.8 42.7
RE-COVER II 2014 Dabigatran 150mg twice daily 30/1279 Warfarin 28/1289 56.5 39.4
https://doi.org/10.1371/journal.pone.0197583.t001
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from those receiving warfarin on the odds of recurrent VTE and related death (the primary
outcome in most studies of secondary prevention in acute VTE), but this primary outcome
showed a tendency to favor DOACs (OR 0.88, CI 0.75–1.03). Similarly, the two groups did not
differ in their risk of dying from all causes or their risk for a recurrent DVT, fatal PE, or recur-
rent non-fatal PE (Fig 4).
Recipients of a DOAC also had a favorable net clinical benefit (0.72, 0.61–0.85), but they
experienced greater risk of developing a myocardial infarction (OR 2.44, CI 1.01–5.87) than
participants randomized to receive warfarin therapy, although the absolute risk was no greater
than 0.3%. This relatively higher risk of myocardial infarction persisted when the analysis was
restricted to the use of Factor Xa inhibitors alone (OR 3.00, CI 0.81–11.13).
Participants randomized to receive a DOAC had 36% lower odds of an episode of major
bleeding, 71% lower odds of fatal bleeding, and 64% lower odds of intracranial bleeding, as
well as significantly lower odds of other ADEs such as hepatic transaminase elevations (defined
as serum alanine aminotransferase (ALT) level greater than three times the upper limit of nor-
mal). In contrast to participants with NVAF, participants treated for an acute VTE with a
DOAC did not differ significantly from those treated with warfarin therapy on the odds of
experiencing a GI bleed (Fig 5).
Fig 2. Forest plot of pooled odds ratios (with 95% CI) of various efficacy outcomes for FDA-approved direct oral anticoagulants versus warfarin for
thromboembolic stroke prophylaxis in non-valvular atrial fibrillation.
https://doi.org/10.1371/journal.pone.0197583.g002
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Discussion
This systematic review and meta-analysis provides an updated and pooled analysis of efficacy
and safety outcomes related to the use of FDA-approved DOACs (the direct thrombin inhibi-
tor dabigatran and the factor Xa inhibitors apixaban, rivaroxaban, and edoxaban), in compari-
son with Vitamin K-antagonist-based therapies, for thromboembolic stroke prophylaxis in
patients with NVAF and in treatment of patients with acute VTE (DVT with or without PE).
Our analysis showed that patients with NVAF who received one of the 4 approved DOACs
for stroke prevention had significantly lower odds of developing a stroke or systemic embo-
lism; in particular, the risk of hemorrhagic stroke was less than half that for those treated with
warfarin. Patients on DOACs also experienced significantly lower risk of dying and of develop-
ing ADEs, such as a major or fatal bleeding episode, but were at higher risk for GI bleeding
than those who were treated with warfarin therapy. In comparison, patients receiving DOACs
for management of their acute VTE did not differ significantly from those treated with warfa-
rin in their risk of recurrent VTE and/or death. On the other hand, patients treated with
DOACs still experienced a favorable net clinical benefit, primarily because of lower odds of
developing all ADEs associated with DOACs. In patients with NVAF, the pooled odds ratio
for myocardial infarction was 0.94 (0.83–1.08). Among the four DOACs only dabigatran had
an odds ratio for myocardial infarction greater than 1, but the CIs for all four study-level odds
Fig 3. Forest plot of pooled odds ratios (with 95% CI) of various adverse drug events for FDA-approved direct oral anticoagulants versus warfarin for
thromboembolic stroke prophylaxis in non-valvular atrial fibrillation.
https://doi.org/10.1371/journal.pone.0197583.g003
Efficacy and safety of direct oral anticoagulants
PLOS ONE | https://doi.org/10.1371/journal.pone.0197583 May 24, 2018 8 / 14
ratios included 1, and the pooled odds ratio after excluding dabigatran was 0.88 (0.76–1.02).
The available evidence does not establish a difference in the risk of myocardial infarction
between the direct thrombin inhibitors and the Factor Xa inhibitors. More generally, useful
comparisons of the efficacy and safety profiles among the four DOACs require additional tri-
als, preferably head-to-head comparisons.
Prior systematic reviews and meta-analyses have examined the efficacy and safety of
DOACs in patients with various cardiac and non-cardiac conditions. Since the rates of bleed-
ing vary widely between cardiovascular indications and post-operative VTE-prevention indi-
cations, however, we did not include trials of patients with non-cardiovascular indications in
our systematic review and meta-analysis.
Many of those meta-analyses have only a weak connection to the question that motivated
our work. They included data from Phase 2 trials or data for DOACs at dosages not approved
by the FDA or for anticoagulants other than DOACs and VKAs, or they combined trials in
NVAF or VTE with trials in other cardiovascular conditions, as well as trials in such indica-
tions as DVT prophylaxis in hip or knee replacement.
Further, several prior meta-analyses included trials of DOACs for off-label indications,
including the prevention of VTE in medically ill patients and treatment of patients with an
acute coronary syndrome[34, 35]. Also, several prior meta-analyses included DOACs, such as
Fig 4. Forest plot of pooled odds ratios (with 95% CI) of various efficacy outcomes for FDA-approved direct oral anticoagulants versus warfarin for treatment of
VTE.
https://doi.org/10.1371/journal.pone.0197583.g004
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darexaban and betrixaban, that either have not been approved for use or have been withdrawn
from the market. Even among studies that did not have such broader inclusion criteria and
related shortcomings, many used methods of analysis that are known to produce unreliable
results (S10 File discusses the prior reviews and their limitations). Thus, most prior meta-anal-
yses do not provide usable evidence for the objectives of our systematic review and meta-analy-
sis, even if their results are similar to ours. The main exceptions are two network meta-
analyses[36], but they did not produce results for DOACs as a class vs. warfarin.
By including only currently FDA-approved DOACs at FDA-approved doses. using sound
analytical methods, and providing a contemporary picture of treatment efficacy and safety,
our review and analysis support including DOACs in the clinician’s armamentarium for pre-
vention or treatment of thromboembolic disease in most patients. Further, current practice
guidelines for management of anticoagulation in patients with NVAF and VTE[6–10] encour-
age a shared decision-making process to present personalized risk estimates to individual
patients and solicitation of their concerns about treatment prior to recommending long-term
preventive therapies. We recommend giving eligible patients and their families information
about the risks and benefits of DOACs, along with one’s expert opinion on their expected net
clinical benefit, when discussing options for oral anticoagulation treatment.
Fig 5. Forest plot of pooled odds ratios (with 95% CI) of various adverse drug events for FDA-approved direct oral anticoagulants versus warfarin for treatment
of VTE.
https://doi.org/10.1371/journal.pone.0197583.g005
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Study strengths and limitations
The major strengths of this meta-analysis are its focus on efficacy and safety outcomes related
to the use of DOACs in comparison with warfarin-based anticoagulation strategies, its inclu-
sion of all DOACs currently approved for treatment in patients with NVAF and VTE at FDA-
approved dosages, its reliance on data from high-quality Phase 3 randomized controlled trials,
and its use of sound statistical methods.
Even high-quality Phase 3 trials, however, can differ in ways that add uncertainty to the
results and interpretation of a meta-analysis. For example, in the NVAF trials, patients who
were treated with warfarin therapy in the ROCKET AF trial had an INR in the therapeutic
range (2.0–3.0) for a smaller percentage of the time (median 58%) than those in the ARIS-
TOTLE, ENGAGE AF-TIMI 48, and RE-LY trials. Trial inclusion and exclusion criteria can
also create disparities and confusion in data interpretation. In making indirect comparisons
among apixaban, dabigatran, and rivaroxaban in NVAF, Schneeweiss et al.[37] focused on the
baseline CHADS2 score in the warfarin control groups: 87% of patients in the ROCKET AF
trial had scores3, versus 30% in the ARISTOTLE trial and 32% in the RE-LY trial. The inves-
tigators dealt with these important discrepancies by using data for the subset of patients in the
ARISTOTLE and RE-LY trials with CHADS2 score3. This type of departure from compara-
bility may have less impact on pairwise meta-analysis than on indirect comparisons, but it
would be useful to carry out a meta-analysis for the subset of patients in all 4 NVAF trials with
CHADS2 scores3. As far as we are aware, however, these data for the ARISTOTLE,
ENGAGE AF-TIMI 48, and RE-LY trials are not publicly available.
Several DOACs either have been withdrawn from the market or were not approved for use
at certain doses because of their high risk-to-benefit ratio or ADEs observed in preliminary tri-
als. Use of data from these studies would probably have led to overestimation of ADE risks for
DOACs. Finally, the population of participants in the EINSTEIN-PE trial[38] differed suffi-
ciently from those in the 5 VTE trials that we excluded this study from the current analysis.
Although we have included data from all relevant Phase 3 randomized trials published to
date, the number of trials is modest; results from ongoing trials and post-market surveillance
studies should be considered as such data become available.
Conclusions
In our contemporary analysis including all Phase 3 clinical trials examining the efficacy and
safety of DOACs, particularly when used for FDA-approved cardiovascular indications and
dosages, DOACs as a class were associated with a superior, or at least comparable, efficacy pro-
file and with substantially lower odds of bleeding complications than warfarin-based anticoa-
gulation strategies. Participants treated with DOACs also experienced either comparable or
lower odds of dying from all causes, depending on the indication. With the exception of higher
odds of GI bleeding among trial participants with NVAF who received rivaroxaban or dabiga-
tran, the overall safety profile of DOACs was favorable in comparison with warfarin. We there-
fore conclude that DOACs should be considered as safe and effective alternatives to warfarin
therapy in patients with NVAF and VTE.
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